Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

• Published in: Alzheimer's research & therapy Vol. 10; no. 1; pp. 107 - 14
• Main Authors: Scheltens, Philip, Hallikainen, Merja, Grimmer, Timo, Duning, Thomas, Gouw, Alida A, Teunissen, Charlotte E, Wink, Alle Meije, Maruff, Paul, Harrison, John, van Baal, Caroline M, Bruins, Suzanne, Lues, Inge, Prins, Niels D
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.10.2018; BioMed Central; BMC
• Subjects: Aging; Alzheimer's disease; Animal cognition; Biomarkers; Brain research; Cognitive ability; Dementia; Diagnosis; Double-blind studies; Electroencephalography; Enzymes; Glutaminyl cyclase inhibitor; Multivariate analysis; Neurotoxicity; Phase 2a; PQ912; Risk factors; Systematic review; Glutaminyl cyclase inhibitor; Phase 2a; Alzheimer’s disease; PQ912
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-018-0431-6

PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in the formation of synaptotoxic pyroglutamate-A-beta oligomers. We report on the first clinical study with PQ912 in subjects with biomarker-proven Alzheimer's disease (AD). The aim was to determine the maximal tol...